Nefazodone

• Description:

  Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction[1][2][3].

• UNSPSC:

  12352005

• Target:

  5-HT Receptor; Cytochrome P450

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/nefazodone.html

• Purity:

  98.01

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C1N(N=C(N1CCOC2=CC=CC=C2)CC)CCCN3CCN(CC3)C4=CC=CC(Cl)=C4

• Molecular Formula:

  C25H32ClN5O2

• Molecular Weight:

  470.01

• References & Citations:

  [1]Dykens JA, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci. 2008 Jun;103 (2) :335-45.|[2]Freire-Garabal M, et al. Effects of nefazodone on the immune system of mice. Eur Neuropsychopharmacol. 2000 Jul;10 (4) :255-64.|[3]Davis R, et al. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53 (4) :608-36.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT2 Receptor

• CAS Number:

  [83366-66-9]